Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research

BACKGROUNDS: Patients who develop an active tuberculosis infection during tumor necrosis factor (TNF) inhibitor treatment typically discontinue TNF inhibitor and receive standard anti-tuberculosis treatment. However, there is currently insufficient information on patient outcomes following resumptio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hye Won, Kwon, Seong Ryul, Jung, Kyong-Hee, Kim, Seong-Kyu, Baek, Han Joo, Seo, Mi Ryung, Bang, So-Young, Lee, Hye-Soon, Suh, Chang-Hee, Jung, Ju Yang, Son, Chang-Nam, Shim, Seung Cheol, Lee, Sang-Hoon, Lee, Seung-Geun, Lee, Yeon-Ah, Lee, Eun Young, Kim, Tae-Hwan, Kim, Yong-Gil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839632/
https://www.ncbi.nlm.nih.gov/pubmed/27101309
http://dx.doi.org/10.1371/journal.pone.0153816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839632/
https://www.ncbi.nlm.nih.gov/pubmed/27101309
http://dx.doi.org/10.1371/journal.pone.0153816

Ejemplares similares